Imatinib, a BCR‐ABL tyrosine kinase inhibitor (TKI), has significantly changed the treatment landscape of Philadelphia chromosome‐positive chronic myeloid leukemia (CML). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.